Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report published on Thursday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

ADXS opened at $0.03 on Thursday. Ayala Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $1.49. The company has a 50-day moving average of $0.04 and a 200-day moving average of $0.09. The company has a market capitalization of $1.15 million, a P/E ratio of 0.00 and a beta of 1.70.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.